NAMS Menopause Certification Exam
(MSCP) Practice Test Bank | Core
Concepts 1-400 | Domain 3 Complete
Review Guide (Latest 2026/2027)
This high-yield Stuvia study resource contains
400 comprehensive practice questions
meticulously aligned with Domain 3 (Health
Disorders Associated with Menopause) of the
NAMS Menopause Society Certified Practitioner
(MSCP) exam blueprint. Every entry features
distinct, standardized question blocks, bolded
multi-choice selections, verified answers, and
detailed expert rationales to optimize retention.
Covering critical midlife conditions including
postmenopausal osteoporosis, fracture risk
indices (FRAX), atherogenic lipid shifts,
metabolic syndrome, and cardiovascular disease
risk, this guide guarantees a seamless upload
and a passing score on your initial exam
attempt.
PART 1: PHYSIOLOGY AND PATHOPHYSIOLOGY OF THE
MENOPAUSE TRANSITION
,(Domain 1 – ≈ 19% of exam, Questions 1–57)
Question 1
What is the "climacteric phase"?
A) The final menstrual period
B) The period of endocrinologic, somatic, and transitory psychologic changes around
the time of menopause
C) The perimenopause only
D) The postmenopausal period
Correct Answer: B
Rationale: The climacteric phase encompasses the entire transitional phase
spanning perimenopause into early postmenopause. It is characterized by
progressive endocrinologic decline, somatic symptoms, and psychological
adjustments as biological ovarian function decreases.
Question 2
During the early menopause transition (Stages -2 to -1 on the STRAW+10 scale), which
physiological hormone change is characteristically observed first?
A) An immediate, permanent drop in serum estrone levels
B) Wide fluctuations in estradiol levels accompanied by an intermittent rise in follicle-
stimulating hormone (FSH)
C) Complete absence of serum progesterone levels throughout the calendar year
D) Severe elevation of thyroid-stimulating hormone (TSH)
Correct Answer: B
Rationale: The early menopause transition is characterized by irregular menstrual
cycles and highly variable hormonal profiles. Estradiol levels exhibit
unpredictable spikes and drops due to erratic follicular recruitment, which
triggers feedback mechanisms causing intermittent elevations in FSH.
Question 3
Which of the following markers is considered the most reliable clinic-based indicator of
diminished ovarian reserve during premenopausal screening?
A) Inhibin A
B) Total serum testosterone
C) Anti-Müllerian Hormone (AMH)
D) Dehydroepiandrosterone sulfate (DHEA-S)
Correct Answer: C
,Rationale: Anti-Müllerian Hormone (AMH) is produced directly by the granulosa
cells of preantral and small antral follicles. Because it reflects the continuous size
of the remaining primordial follicle pool, a declining AMH level serves as a highly
specific indicator of declining ovarian reserve.
Question 4
Following the final menstrual period (FMP), what becomes the primary circulating
estrogen in postmenopausal women?
A) Estradiol (\(E_{2}\))
B) Estriol (\(E_{3}\))
C) Estrone (\(E_{1}\))
D) Ethinyl estradiol
Correct Answer: C
Rationale: In premenopausal women, estradiol (\(E_{2}\)) secreted by the ovaries
is the dominant estrogen. Post-menopause, direct ovarian estrogen synthesis
drops dramatically, and estrone (\(E_{1}\)), formed primarily via the peripheral
conversion of adrenal androstenedione in adipose tissue, becomes the primary
circulating estrogen.
Question 5
What is the standard clinical definition utilized to confirm that a woman has reached
menopause?
A) A single elevated serum FSH level greater than 50 IU/L
B) 6 consecutive months of oligomenorrhea accompanied by hot flashes
C) 12 consecutive months of spontaneous amenorrhea with no other pathological or
physiological cause
D) The complete surgical removal of one ovary
Correct Answer: C
Rationale: Menopause is a retrospective clinical diagnosis defined as 12
consecutive months of spontaneous amenorrhea resulting from the permanent
loss of ovarian follicular activity. Biochemical markers are generally unnecessary
for confirmation unless a confounding variable is present.
, Question 6
According to the STRAW+10 staging system, what is the hallmark feature defining the
entry into the late menopause transition (Stage -1)?
A) The onset of hot flashes and night sweats
B) A variable cycle length that differs by 7 or more days from baseline
C) The occurrence of amenorrhea lasting 60 consecutive days or more
D) A sustained drop in serum follicle-stimulating hormone (FSH) levels
Correct Answer: C
Rationale: Entry into the late menopause transition (Stage -1) is marked by the
occurrence of amenorrhea lasting 60 consecutive days or more. A cycle length
variation of 7 or more days defines the early transition stage (Stage -2).
Question 7
Which ovarian peptide hormone, which normally exerts negative feedback on FSH
secretion, drops significantly during the menopause transition?
A) Inhibin B
B) Luteinizing hormone (LH)
C) Relaxin
D) Prolactin
Correct Answer: A
Rationale: Inhibin B is produced by the granulosa cells of developing follicles and
keeps FSH in check. As the antral follicle count drops with aging, Inhibin B
production falls, which removes the negative feedback loop and causes the rise
in early-cycle FSH levels.
Question 8
In postmenopausal women, what tissue site handles the greatest total production of
estrone (\(E_{1}\))?
A) Adrenal cortex
B) Anterior pituitary gland
C) Adipose tissue
D) Endometrium
Correct Answer: C
Rationale: After ovarian failure, peripheral aromatization of adrenal
androstenedione into estrone takes place primarily within adipose tissue. This
(MSCP) Practice Test Bank | Core
Concepts 1-400 | Domain 3 Complete
Review Guide (Latest 2026/2027)
This high-yield Stuvia study resource contains
400 comprehensive practice questions
meticulously aligned with Domain 3 (Health
Disorders Associated with Menopause) of the
NAMS Menopause Society Certified Practitioner
(MSCP) exam blueprint. Every entry features
distinct, standardized question blocks, bolded
multi-choice selections, verified answers, and
detailed expert rationales to optimize retention.
Covering critical midlife conditions including
postmenopausal osteoporosis, fracture risk
indices (FRAX), atherogenic lipid shifts,
metabolic syndrome, and cardiovascular disease
risk, this guide guarantees a seamless upload
and a passing score on your initial exam
attempt.
PART 1: PHYSIOLOGY AND PATHOPHYSIOLOGY OF THE
MENOPAUSE TRANSITION
,(Domain 1 – ≈ 19% of exam, Questions 1–57)
Question 1
What is the "climacteric phase"?
A) The final menstrual period
B) The period of endocrinologic, somatic, and transitory psychologic changes around
the time of menopause
C) The perimenopause only
D) The postmenopausal period
Correct Answer: B
Rationale: The climacteric phase encompasses the entire transitional phase
spanning perimenopause into early postmenopause. It is characterized by
progressive endocrinologic decline, somatic symptoms, and psychological
adjustments as biological ovarian function decreases.
Question 2
During the early menopause transition (Stages -2 to -1 on the STRAW+10 scale), which
physiological hormone change is characteristically observed first?
A) An immediate, permanent drop in serum estrone levels
B) Wide fluctuations in estradiol levels accompanied by an intermittent rise in follicle-
stimulating hormone (FSH)
C) Complete absence of serum progesterone levels throughout the calendar year
D) Severe elevation of thyroid-stimulating hormone (TSH)
Correct Answer: B
Rationale: The early menopause transition is characterized by irregular menstrual
cycles and highly variable hormonal profiles. Estradiol levels exhibit
unpredictable spikes and drops due to erratic follicular recruitment, which
triggers feedback mechanisms causing intermittent elevations in FSH.
Question 3
Which of the following markers is considered the most reliable clinic-based indicator of
diminished ovarian reserve during premenopausal screening?
A) Inhibin A
B) Total serum testosterone
C) Anti-Müllerian Hormone (AMH)
D) Dehydroepiandrosterone sulfate (DHEA-S)
Correct Answer: C
,Rationale: Anti-Müllerian Hormone (AMH) is produced directly by the granulosa
cells of preantral and small antral follicles. Because it reflects the continuous size
of the remaining primordial follicle pool, a declining AMH level serves as a highly
specific indicator of declining ovarian reserve.
Question 4
Following the final menstrual period (FMP), what becomes the primary circulating
estrogen in postmenopausal women?
A) Estradiol (\(E_{2}\))
B) Estriol (\(E_{3}\))
C) Estrone (\(E_{1}\))
D) Ethinyl estradiol
Correct Answer: C
Rationale: In premenopausal women, estradiol (\(E_{2}\)) secreted by the ovaries
is the dominant estrogen. Post-menopause, direct ovarian estrogen synthesis
drops dramatically, and estrone (\(E_{1}\)), formed primarily via the peripheral
conversion of adrenal androstenedione in adipose tissue, becomes the primary
circulating estrogen.
Question 5
What is the standard clinical definition utilized to confirm that a woman has reached
menopause?
A) A single elevated serum FSH level greater than 50 IU/L
B) 6 consecutive months of oligomenorrhea accompanied by hot flashes
C) 12 consecutive months of spontaneous amenorrhea with no other pathological or
physiological cause
D) The complete surgical removal of one ovary
Correct Answer: C
Rationale: Menopause is a retrospective clinical diagnosis defined as 12
consecutive months of spontaneous amenorrhea resulting from the permanent
loss of ovarian follicular activity. Biochemical markers are generally unnecessary
for confirmation unless a confounding variable is present.
, Question 6
According to the STRAW+10 staging system, what is the hallmark feature defining the
entry into the late menopause transition (Stage -1)?
A) The onset of hot flashes and night sweats
B) A variable cycle length that differs by 7 or more days from baseline
C) The occurrence of amenorrhea lasting 60 consecutive days or more
D) A sustained drop in serum follicle-stimulating hormone (FSH) levels
Correct Answer: C
Rationale: Entry into the late menopause transition (Stage -1) is marked by the
occurrence of amenorrhea lasting 60 consecutive days or more. A cycle length
variation of 7 or more days defines the early transition stage (Stage -2).
Question 7
Which ovarian peptide hormone, which normally exerts negative feedback on FSH
secretion, drops significantly during the menopause transition?
A) Inhibin B
B) Luteinizing hormone (LH)
C) Relaxin
D) Prolactin
Correct Answer: A
Rationale: Inhibin B is produced by the granulosa cells of developing follicles and
keeps FSH in check. As the antral follicle count drops with aging, Inhibin B
production falls, which removes the negative feedback loop and causes the rise
in early-cycle FSH levels.
Question 8
In postmenopausal women, what tissue site handles the greatest total production of
estrone (\(E_{1}\))?
A) Adrenal cortex
B) Anterior pituitary gland
C) Adipose tissue
D) Endometrium
Correct Answer: C
Rationale: After ovarian failure, peripheral aromatization of adrenal
androstenedione into estrone takes place primarily within adipose tissue. This
